Global Albumin Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Albumin Market Analysis

The albumin market is experiencing dynamic growth, driven by increasing applications in therapeutics, drug delivery, and culture media A notable development in the market is the advancement in plasma fractionation technologies, which improve both the efficiency and yield of albumin production. For instance, companies such as Kedrion Biopharma are expanding their human serum albumin offerings in emerging markets such as China to address the needs for rare disease treatments. Additionally, the shift towards recombinant albumin, produced through genetic engineering, is gaining traction due to its superior safety profile and consistency compared to traditional human serum albumin. Such trend is exemplified by Grifols' introduction of Albutein, which is increasingly used in clinical research and pharmaceutical applications. Moreover, growing investment in research and development, particularly in North America, is accelerating innovation and improving production processes. Inclusive advancements collectively contribute to the robust growth and diversification of the albumin market, meeting the evolving demands of the healthcare and research sectors.

Albumin Market Size

The global albumin market size was valued at USD 1.01  billion in 2023 and is projected to reach USD 1.62  billion by 2031, with a CAGR of 6.00% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Albumin Market Trends

“Rising Use of Recombinant Albumin”

The global albumin market is witnessing significant growth, influenced by advancements in production and increasing demand for therapeutic applications. A prominent trend in the market is the rising use of recombinant albumin. Unlike traditional human serum albumin, recombinant albumin is produced using genetic engineering techniques, offering enhanced purity and reduced risk of contamination. For instance, Grifols has been at the forefront with its recombinant albumin product, Albutein, which is utilized in various medical treatments including drug delivery systems and clinical research. Such shift towards recombinant albumin is driven by the need for safer and more consistent therapeutic options. The growing emphasis on high-quality, contamination-free products is expected to further propel market growth, as healthcare providers and researchers increasingly adopt these advanced solutions to meet the evolving demands of patient care and scientific inquiry.

Report Scope and Albumin Market Segmentation     

Albumin Market Definition

Albumin is a type of protein found in blood plasma that plays a crucial role in maintaining the osmotic pressure necessary for proper distribution of body fluids between blood vessels and tissues. It is produced primarily in the liver and is essential for various physiological functions, including transporting hormones, vitamins, and drugs through the bloodstream. Albumin also helps in stabilizing blood volume and pressure. In medical applications, albumin is used as a therapeutic agent to treat conditions such as liver disease, kidney disease, and shock, as well as in drug delivery systems and clinical research.

Albumin Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases significantly drives the demand for albumin-based therapies. For instance, the World Health Organization reported in 2023 that chronic liver disease is responsible for nearly 2 billion deaths annually, with liver cirrhosis being a leading cause. In the United States alone, approximately 1.2 billion people are affected by liver cirrhosis, highlighting the need for effective management strategies. Albumin is crucial in these conditions for stabilizing blood volume and improving fluid balance, thereby supporting patient outcomes. Additionally, the prevalence of chronic kidney disease affects over 10% of the global population, with an estimated 840 billion individuals, according to the Global Burden of Disease Study. This widespread occurrence drives the need for albumin therapies to manage complications such as hypoalbuminemia. These figures emphasize the essential role of albumin in addressing chronic diseases and underscore its growing importance in therapeutic interventions.

• Expansion of Healthcare Infrastructure

The expansion of healthcare infrastructure in emerging markets is a crucial driver of growth in the global albumin market. For instance, India's healthcare sector is anticipated to reach USD 370 billion by 2025, supported by significant improvements in hospital networks and enhanced access to advanced medical care. This burgeoning infrastructure includes the development of state-of-the-art medical facilities and the introduction of innovative treatments, which elevate the availability of specialized therapies such as albumin-based products. Consequently, the growing investment in healthcare infrastructure not only boosts the reach of albumin therapies but also supports the overall market expansion by addressing the increasing demand for effective medical solutions across diverse patient populations. Such trend underscores the vital role of infrastructure development in driving the global albumin market forward.

Opportunities

• Growing Use in Drug Delivery Systems

The growing use of albumin in drug delivery systems is significantly enhancing therapeutic efficacy due to its unique properties as a transport protein. Albumin's ability to bind and carry a variety of therapeutic agents makes it ideal for improving the targeting and release of drugs within the body. For instance, Abraxane, an albumin-bound formulation of paclitaxel, is used in cancer treatment to deliver the drug directly to tumor cells more effectively than conventional paclitaxel formulations. Such targeted approach not only increases the drug's bioavailability but also reduces side effects by minimizing exposure to healthy tissues. As the demand for more precise and efficient drug delivery methods rises, albumin's role continues to expand, driven by its capacity to enhance the delivery and effectiveness of therapeutic agents while improving patient outcomes.

• Advancements in Plasma Fractionation Technology

Advancements in plasma fractionation technology are significantly improving the efficiency and yield of albumin production, leading to a greater availability of high-quality albumin products. Modern fractionation techniques, such as the use of high-resolution chromatography and advanced filtration methods, have revolutionized the separation and purification of plasma proteins. For instance, Octapharma has implemented cutting-edge fractionation processes that enhance the purity and yield of albumin extracted from plasma, resulting in a more reliable and consistent product. Such technological improvements not only increase the volume of albumin available for therapeutic use but also ensure higher quality and safety standards, meeting the growing demand for albumin-based treatments. As these innovations continue to evolve, they play a crucial role in expanding the global supply of albumin and supporting its application in various medical and research settings.

Restraints/Challenges

• Regulatory Hurdles and Stringent Requirements

Regulatory hurdles are a significant challenge in the albumin market, where stringent requirements can impede market entry and elevate operational costs. For instance, to gain approval from the U.S. Food and Drug Administration (FDA), albumin products must undergo extensive clinical trials and meet detailed documentation standards. According to a 2023 report by the FDA, the average time for a new biologics license application to be reviewed is approximately 10 months. Similarly, the European Medicines Agency (EMA) requires compliance with the European Union's Regulation (EC) No 726/2004 and the guidelines outlined in the "European Pharmacopoeia," demanding comprehensive safety and efficacy data. Such rigorous standards can delay product launches and significantly increase development costs. Compliance with these regulatory frameworks necessitates substantial investments in research, quality control, and documentation, affecting both time-to-market and the financial viability of new albumin products.

• Absurd Uses and Adverse Reactions Associated with Albumin

The rising challenge in the albumin market is the occurrence of adverse reactions and the reporting of unusual uses associated with albumin. Administration of albumin can lead to allergic reactions, febrile non-hemolytic transfusion reactions (FNHTR), and anaphylaxis. Additionally, there are concerns about the misuse of albumin in non-medical applications, such as certain cosmetic procedures and unregulated treatments, which pose potential health risks. The World Health Organization (WHO) has emphasized the need for stringent regulations and monitoring to address these issues. Consequently, such factors can hinder market growth by impacting safety and regulatory compliance.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Albumin Market Scope

The market is segmented on the basis of type, application, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Human Serum Albumin
• Bovine Serum Albumin
• Recombinant Albumin

Application

• Therapeutics
• Vaccine Ingredient
• Drug Delivery
• Culture Media
• Others

End User

• Hospitals
• Clinics
• Pharmaceutical and Biotechnology Companies
• Research Institutes

Albumin Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, application, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

The Asia-Pacific region dominates the albumin market due to its large and rapidly growing population, coupled with a significant emphasis on advancing diagnostic capabilities, preventive treatments, and medical research. The region's expanding healthcare infrastructure and increasing investments in research and development further drive the demand for albumin products.

North America is projected to experience substantial growth from 2024 to 2031, driven by the increasing establishment of plasma fractionation facilities which boost albumin production. Additionally, the region's heightened investment in research and development further supports this expansion. These factors collectively contribute to North America's robust growth outlook in the albumin market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Albumin Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Albumin Market Leaders Operating in the Market Are:

• Octapharma AG (Switzerland)
• CSL (Australia)
• Baxter (U.S.)
• HiMedia Laboratories (India)
• MedxBio Pte Ltd (Singapore)
• Novozymes A/S (Denmark)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Merck KGaA (Germany)
• Akron Biotech (U.S.)
• China Biologic Products Holdings, Inc. (China)
• Thermo Fisher Scientific Inc. (U.S.)
• Thrive Supplements (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Kedrion S.p.A (Italy)
• Grifols, S.A. (Spain)
• InVitria (U.S.)
• Albumin Therapeutics, LLC (U.S.)
• RayBiotech, Inc. (U.S.)
• LGC Clinical Diagnostics (U.K.)

Latest Developments in Albumin Market

• In August 2022, Sartorius AG completed the acquisition of Albumedix Ltd., a leading U.K.-based manufacturer specializing in recombinant human albumin-based products. This strategic acquisition is set to significantly enhance Sartorius AG’s product portfolio, particularly in the field of recombinant-based solutions.
• In July 2023, Kedrion Biopharma, a global leader in plasma-derived therapeutics, revealed plans to expand its range of human serum albumin products in China. This strategic move aims to address the growing need for treatments of rare diseases in the region. By enhancing its presence in the Chinese market, Kedrion Biopharma seeks to improve access to crucial therapeutic products for patients with specialized medical needs.

SKU-30377